• All Categories
  • Analytics
  • Digital
  • Discovery and Development
  • Manufacturing
  • Laboratory Automation
  • Press Releases
  • Features
  • Microscopy
  • Conferences and Events
  • IPT TV
  • Product Profile
Ilmac: Inspiring the Future of Chemistry and Life Sciences
Ilmac: Inspiring the Future of Chemistry and Life Sciences

Next Ilmac in Lausanne: 18 and 19 September 2024 | Beaulieu Lausanne Next Ilmac in Basel: 16 - 18 September 2025 | Messe Basel, Hall 1.0 All information at: www.ilmac.ch

16 April 2024IPT TV
ELRIG UK and SRG Announce Partnership to Advance Life Science Professionals in Drug Discovery
ELRIG UK and SRG Announce Partnership to Advance Life Science Professionals in Drug Discovery

The European Laboratory Research & Innovation Group (ELRIG) UK, a not-for-profit, volunteer-led organisation for the drug discovery community, today entered into a partnership with SRG, leaders in life science recruitment, to support the advancement of science professionals in their careers.

15 April 2024Press Releases
INTERPHEX Conference Brings High-Value Research to 2024 Attendees
INTERPHEX Conference Brings High-Value Research to 2024 Attendees

INTERPHEX, the premier pharmaceutical and biotechnology event taking place April 16-18, 2024, at the Javits Center in NYC, is proud to introduce INTERPHEX Conference, an all-new, transformative event that will enrich the meeting experience for attendees, starting in 2024.

9 April 2024IPT TV
Intro to USP <1062>: What it is and why you should use it
Intro to USP <1062>: What it is and why you should use it

A variety of factors like powder flow, material characteristics, compression pressure, turret speed, etc can affect tablet quality and production run time. Any resulting tablet defects can exacerbate production costs or even result in no product at all! Therefore, it’s necessary to characterise the tablet compression process to achieve robust tablets.

2 April 2024Press Releases
Ubiquigent and Debiopharm Enter Agreement to Support USP1 Inhibitor Programme for Debio 0432
Ubiquigent and Debiopharm Enter Agreement to Support USP1 Inhibitor Programme for Debio 0432

: Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced an agreement with Debiopharm, a biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases. The agreement will support the development of Debiopharm’s USP1 inhibitor programme, Debio 0432.

26 March 2024Press Releases
Teva UK and Closed Loop Medicine announce strategic partnership to advance development of personalis
Teva UK and Closed Loop Medicine announce strategic partnership to advance development of personalis

Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicine.

26 March 2024Press Releases
ArgusEye introduces AugaOne to accelerate downstream bioprocess development
ArgusEye introduces AugaOne to accelerate downstream bioprocess development

ArgusEye, a provider of innovative sensor solutions for real-time monitoring of biological systems, today announced the introduction of the AugaOne™ sensor system. AugaOne is the first product in the Company’s sensor system platform, Auga™, and is tailored to accelerate downstream monoclonal antibody (mAb) process development by providing specific real-time and automated in-line data with high sensitivity, without requiring sample pretreatment.

25 March 2024Press Releases
 CARBOGEN AMCIS announces successful ANVISA audit of its facility in China
CARBOGEN AMCIS announces successful ANVISA audit of its facility in China

Between 6-10th November 2023, a five-day inspection was undertaken, which concluded successfully with no critical and no major observations raised. A Good Manufacturing Practice (GMP) certificate has been granted to the site by the authority

20 March 2024Press Releases
Semarion introduces SemaCyte Multiplexing Platform to enhance cell assay data quality and speed duri
Semarion introduces SemaCyte Multiplexing Platform to enhance cell assay data quality and speed duri

Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, today introduced its SemaCyte® Multiplexing Platform, an expansion to the existing SemaCyte Microcarrier platform to utilize optical barcoding to accelerate screening processes during in vitro drug discovery.

20 March 2024Press Releases
 SolasCure Awarded £405K Innovate UK Biomedical Catalyst Grant to Advance Chronic Wound Care
SolasCure Awarded £405K Innovate UK Biomedical Catalyst Grant to Advance Chronic Wound Care

SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound care, today announced it has been awarded a highly competitive Biomedical Catalyst grant for industry-led research and development (R&D) from Innovate UK, the UK’s innovation agency.

20 March 2024Press Releases
SICK Develops OD7000 Precision Sensor for Demanding Micron Measurements
SICK Develops OD7000 Precision Sensor for Demanding Micron Measurements

Developed for ultra-high precision in the micron range, SICK’s innovative and compact OD7000 displacement sensor reliably measures tiny distances in challenging applications cost-effectively. Comprising a separate controller and sensor head that are both extremely compact, the OD7000 is purpose-built to fit into the tightest machine spaces. The SICK OD7000 is a 1D laser distance sensor that measures differences in height accurately even on challenging materials.

20 March 2024Press Releases
Nuclera Joins Tech Nation’s Future Fifty Program
Nuclera Joins Tech Nation’s Future Fifty Program

Nuclera, the biotechnology company enabling rapid protein expression and purification screening through its eProtein Discovery benchtop protein platform, today announced it has been selected to join the Tech Nation Future Fifty 2024 cohort, a unique program designed for the UK’s next generation of unicorn founders, recognizing the most promising late-stage technology ventures.

19 March 2024Press Releases